Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255494 | 0.87 | HTR2A (0.44) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL21477662 | 0.86 | HTR2A (0.42) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL14811440 | 0.84 | TNKS2 (0.41) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL12524837 | 0.81 | PTGS2 (0.50) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL14485783 | 0.81 | ABCB1 (0.48) | — | |
| SCHEMBL30716603 | 0.79 | PIK3CA (0.39) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL10948586 | 0.79 | NPC1 (0.41) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL19330349 | 0.79 | PIK3CA (0.39) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL19330511 | 0.79 | NPC1 (0.48) | HTR2AHTR2CHTR2BTAAR1TSHR | |
| SCHEMBL24968405 | 0.78 | HTR2A (0.45) | HTR2AHTR2CHTR2BKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763986-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2017-06-07 | — | — | EP | disclosed |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| WO-2013041458-A1 | FSH RECEPTOR ANTAGONISTS | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| EP-2493299-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120196901-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196901-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2451281-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| WO-2011053522-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011005636-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | HTR2A 41/4885HTR2C 50/4885HTR2B 63/4885 |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | FSHR, GNRHR, LHCGR | HTR2A 1656/4885HTR2C 2103/4885HTR2B 1088/4885 |
| US-20120196901-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HTR2A 73/4885HTR2C 144/4885HTR2B 106/4885 |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | FSHR, GNRHR, LHCGR | HTR2A 1655/4885HTR2C 2018/4885HTR2B 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.